Wyniki wyszukiwania dla: Gideon M. Hirschfield

Pozycje od 1 do 20 spośród 92 wyników

Poprzednia

Następna

artykuł

Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study

Palak J. Trivedi, Katherine Arndtz, Nadir Abbas, Alison Telford, więcej

Alimentary Pharmacology & Therapeutics > 59 > 11 > 1366 - 1375

Background Imaging markers of biliary disease in primary sclerosing cholangitis (PSC) have potential for use in clinical and trial disease monitoring. Herein, we evaluate how quantitative magnetic resonance cholangiopancreatography (MRCP) metrics change over time, as per the natural history of disease. Methods Individuals with PSC were prospectively scanned using non‐contrast MRCP. Quantitative...

artykuł

Featured Cover

Marlyn J. Mayo, John M. Vierling, Christopher L. Bowlus, Cynthia Levy, więcej

Alimentary Pharmacology & Therapeutics > 59 > 2 > i - i

The cover image is based on the Fast Track Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis by Marlyn J. Mayo et al., https://doi.org/10.1111/apt.17755

artykuł

Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis

Marlyn J. Mayo, John M. Vierling, Christopher L. Bowlus, Cynthia Levy, więcej

Alimentary Pharmacology & Therapeutics > 59 > 2 > 186 - 200

Background Seladelpar is a potent and selective peroxisome proliferator‐activated receptor‐δ agonist that targets multiple cell types involved in primary biliary cholangitis (PBC), leading to anti‐cholestatic, anti‐inflammatory and anti‐pruritic effects. Aims To evaluate the long‐term safety and efficacy of seladelpar in patients with PBC. Methods In an open‐label, international, long‐term extension...

artykuł

Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one‐year non‐responders and predicts survival

C. Fiorella Murillo Perez, Stephanie Ioannou, Iman Hassanally, Palak J. Trivedi, więcej

Liver International > 43 > 7 > 1497 - 1506

Background and Aims Patients with primary biliary cholangitis (PBC) and insufficient response to ursodeoxycholic acid (UDCA), currently assessed after 1 year, are candidates for second‐line therapy. The aims of this study are to assess biochemical response pattern and determine the utility of alkaline phosphatase (ALP) at six months as a predictor of insufficient response. Methods UDCA‐treated...

artykuł

Liver transplant‐free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid

Rozanne C. Veer, Maren H. Harms, Christophe Corpechot, Douglas Thorburn, więcej

Alimentary Pharmacology & Therapeutics > 56 > 9 > 1408 - 1418

Background After 1 year of ursodeoxycholic acid (UDCA), patients with primary biliary cholangitis (PBC) may have a normal GLOBE score despite high alkaline phosphatase (ALP) levels. Aim To assess the association between ALP and liver transplantation (LT)‐free survival according to the GLOBE score Methods Among patients with a normal or elevated GLOBE score in the Global PBC cohort, the association...

artykuł

Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis

Surain B. Roberts, Gideon M. Hirschfield, Lawrence J. Worobetz, Catherine Vincent, więcej

Hepatology > 76 > 2 > 303 - 316

Background and Aims We investigated associations between ethnicity, survival, and disease severity in a diverse Canadian cohort of patients with primary biliary cholangitis (PBC). Approach and Results Patients with PBC were included from the Canadian Network for Autoimmune Liver Disease. Ethnicity was defined using a modified list adopted from Statistics Canada, and ethnicities with small samples...

artykuł

The Impact of Primary Liver Disease and Social Determinants in a Mixed Donor Liver Transplant Program: A Single‐Center Analysis

Kristel K. Leung, Audrey Kim, Bettina E. Hansen, Les Lilly, więcej

Liver Transplantation > 27 > 12 > 1733 - 1746

Organ allocation in liver transplantation (LT) remains imperfect. Periodic center reviews ensure programs transparently evaluate the impact of practice on access to transplantation, reflecting, in particular, patient (primary disease, social determinants) and program (deceased versus live donation) factors. Adult Ontario residents waitlisted for first LT at Toronto General Hospital from November 2012...

artykuł

Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver‐Related Mortality Is Higher in Males?

Ana Lleo, Gideon M. Hirschfield

Hepatology > 74 > 4 > 2307 - 2307

artykuł

Editorial: liver disease in secondary care—‘money or your life’. Authors' reply

Surain B. Roberts, Amol A. Verma, Gideon M. Hirschfield

Alimentary Pharmacology & Therapeutics > 54 > 6 > 856 - 857

artykuł

Internal medicine hospitalisations and liver disease: a comparative disease burden analysis of a multicentre cohort

Surain B. Roberts, Bettina E. Hansen, Saeha Shin, Lusine Abrahamyan, więcej

Alimentary Pharmacology & Therapeutics > 54 > 5 > 689 - 698

Background Liver disease is an increasing burden on population health globally. Aims To characterise burden of liver disease among general internal medicine inpatients at seven Toronto‐area hospitals and compare it to other common medical conditions. Methods Data from April 2010 to October 2017 were obtained from hospitals participating in the GEMINI collaborative. Using these cohort data from...

artykuł

Esophageal Stenting as Bridge Therapy to Direct Intrahepatic Portocaval Shunt for Refractory Variceal Bleeding

Kristel K. Leung, Paul D. James, Arash Jaberi, Gideon M. Hirschfield

Hepatology > 73 > 4 > 1618 - 1620

artykuł

Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis

Debashis Haldar, Ashnila Janmohamed, Tim Plant, Matthew Davidson, więcej

Liver International > 41 > 3 > 535 - 544

Background and Aims A variety of auto‐antibody assays are available as part of the clinical care of patients with liver disease. We sought to better understand the clinical utility of immune serological testing in patients with primary biliary cholangitis (PBC). Methods We retrospectively analysed data from 2846 patients investigated for liver disease at a UK liver centre between 2001 and 2017...

artykuł

Genomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities

Benjamin Goeppert, Trine Folseraas, Stephanie Roessler, Matthias Kloor, więcej

Hepatology > 72 > 4 > 1253 - 1266

Background and Aims Lifetime risk of biliary tract cancer (BTC) in primary sclerosing cholangitis (PSC) may exceed 20%, and BTC is currently the leading cause of death in patients with PSC. To open new avenues for management, we aimed to delineate clinically relevant genomic and pathological features of a large panel of PSC‐associated BTC (PSC‐BTC). Approach and Results We analyzed formalin‐fixed,...

artykuł

Review article: pathophysiology and management of primary biliary cholangitis

Kristel K. Leung, Maya Deeb, Gideon M. Hirschfield

Alimentary Pharmacology & Therapeutics > 52 > 7 > 1150 - 1164

Background Primary biliary cholangitis (PBC), an immune‐mediated disease characterised by destruction of intrahepatic bile ducts, results in progressive damage to the biliary tree, cholestasis and ultimately advanced liver disease. In the last decade, advances in practice have improved clinical care, driven novel therapeutic options and improved risk stratification tools. Aims To provide an overview...

artykuł

Risk of gallbladder cancer in patients with primary sclerosing cholangitis and radiographically detected gallbladder polyps

Liselot W. Erp, Morven Cunningham, Manasa Narasimman, Hamideh Ale Ali, więcej

Liver International > 40 > 2 > 382 - 392

Background & Aims Primary sclerosing cholangitis (PSC) is associated with an increased risk of gallbladder cancer (GBC). Gallbladder polyps potentially harbour malignancy and thus international guidelines recommend prophylactic cholecystectomy for gallbladder polyps of any size in patients with PSC. To best inform patient care we sought to quantify the malignant risk of gallbladder polyps in...

artykuł

Reply

Elizabeth C. Goode, Gideon M. Hirschfield, Simon M. Rushbrook

Hepatology > 71 > 1 > 399 - 400

artykuł

Letter: histology is relevant for risk stratification in primary biliary cholangitis

Marco Carbone, Daphne D’Amato, Gideon M. Hirschfield, David E. J. Jones, więcej

Alimentary Pharmacology & Therapeutics > 51 > 1 > 192 - 193

artykuł

Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response

Carla F. Murillo Perez, Gideon M. Hirschfield, Christophe Corpechot, Annarosa Floreani, więcej

Alimentary Pharmacology & Therapeutics > 50 > 10 > 1127 - 1136

Background Fibrosis stage predicts prognosis in patients with chronic liver disease independent of aetiology, although its precise role in risk stratification in patients with primary biliary cholangitis (PBC) remains undefined. Aim To assess the utility of baseline fibrosis stage in predicting long‐term outcomes in the context of biochemical risk stratification Methods In a large and globally...

artykuł

Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus

Vinod S. Hegade, Alexandros Pechlivanis, Julie A. K. McDonald, Douglas Rees, więcej

Liver International > 39 > 5 > 967 - 975

Background and Aims Pruritus is a common symptom in patients with primary biliary cholangitis (PBC) for which ileal bile acid transporter (IBAT) inhibition is emerging as a potential therapy. We explored the serum metabonome and gut microbiota profile in PBC patients with pruritus and investigated the effect of GSK2330672, an IBAT inhibitor. Methods We studied fasting serum bile acids (BAs), autotaxin...

artykuł

Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System

Elizabeth C. Goode, Allan B. Clark, George F. Mells, Brijesh Srivastava, więcej

Hepatology > 69 > 5 > 2120 - 2135

We sought to identify factors that are predictive of liver transplantation or death in patients with primary sclerosing cholangitis (PSC), and to develop and validate a contemporaneous risk score for use in a real‐world clinical setting. Analyzing data from 1,001 patients recruited to the UK‐PSC research cohort, we evaluated clinical variables for their association with 2‐year and 10‐year outcome...

Poprzednia

Następna

Opcje filtrowania

Data publikacji

Ostatni rok (3)
Ostatnie 3 lata (7)

Zamknij

Ustawianie zakresu dat

Podaj zakres dat dla filtrowania wyświetlonych wyników. Możesz podać datę początkową, końcową lub obie daty. Daty możesz wpisać ręcznie lub wybrać za pomocą kalendarza.

Od:

Do:
Ustaw własny zakres dat

INFONA - portal komunikacji naukowej

Wyniki wyszukiwania dla: Gideon M. Hirschfield

Dodaj adresata

Anulowanie wysłania wiadomości

Czy na pewno chcesz anulować wysłanie wiadomości?

Wyślij wiadomość

Opcje filtrowania

Data publikacji

Ustawianie zakresu dat

Podaj zakres dat dla filtrowania wyświetlonych wyników. Możesz podać datę początkową, końcową lub obie daty. Daty możesz wpisać ręcznie lub wybrać za pomocą kalendarza.

Słowa kluczowe

Zbiór danych

Czasopismo

Zgłaszanie błędu / nadużycia

Nieudane wysłanie zgłoszenia

Ułatwienia dostępu